<DOC>
	<DOCNO>NCT01550588</DOCNO>
	<brief_summary>Background hypothesis : The appropriate treatment strategy secondary stroke prevention patient cryptogenic stroke patent foramen ovale ( PFO ) remain challenge . Clinical anatomical variable report risk factor associate stroke recurrence include old age , large PFO , large right-to-left shunting , combine atrial septal aneurysm ( ASA ) , , however , confirmed study . The investigator hypothesize percutaneous closure PFO could effective option secondary prevention cryptogenic stroke patient high-risk PFO . Trial Objective : The primary objective study ass whether percutaneous device closure PFO superior conventional antithrombotic treatment prevent stroke recurrence cryptogenic stroke patient high-risk PFO .</brief_summary>
	<brief_title>Device Closure Versus Medical Therapy Cryptogenic Stroke Patients With High-Risk Patent Foramen Ovale ( DEFENSE-PFO )</brief_title>
	<detailed_description>Selection patient : Among cryptogenic stroke patient , patient identify high risk PFO might define high-risk recurrence ( PFO size ≥ 2 mm atrial septal aneurysm hypermobility TEE ) randomize 1:1 : ) Device closure use Amplatzer device vs. b ) standard medical therapy alone . All patient follow least 2 year . Echocardiography Findings high-risk PFO Digitally , store transesophageal echocardiographic image review analyzed investigator . Using caliper , PFO size measure maximum separation septum primum septum secundum . ASA hypermobility define ≥ 10 mm phasic septal excursion either atrium sum total excursion ≥ 15 mm cardiorespiratory cycle , base ≥ 15 mm . Web-based 1:1 blind randomization - Experimental Percutaneous Device Closure use AMPLATZER PFO Occluder - Active Comparator Standard Medical management use anti-coagulant therapy ( least 3 6 month ) Study Endpoints - Primary outcome - Recurrence nonfatal stroke/vascular death/TIMI-major bleeding - Secondary outcome - Recurrent nonfatal stroke - Vascular death - Major bleeding associate medication - Asymptomatic recurrent ischemic stroke follow-up MR - Complete closure defect demonstrate TEE bubble study ( device group ) Frequency residual shunt , ( ) correct device position , need implantation second device peri-procedural complication - Procedure related complication - Medication related complication</detailed_description>
	<mesh_term>Foramen Ovale , Patent</mesh_term>
	<criteria>Subjects cryptogenic stroke within previous 3 month , radiologically verified Subjects diagnose highrisk* Patent Foramen Ovale ( PFO ) , echocardiographically verify ( *PFO size ≥ 2 mm atrial septal aneurysm hypermobility TEE ) Subjects willing participate followup visit Absence potential cause stroke Any identifiable cause thromboembolic cause PFO Subjects intracardiac thrombus tumor , dilate cardiomyopathy , prosthetic heart valve mitral stenosis , endocarditis Subjects significant atherosclerosis dissection aorta , collagen vascular disease , arteritis , vasculitis coagulopathy Subjects acute recent ( within 6 month ) myocardial infarction unstable angina Subjects nonvascular origin neurological symptom brain imaging ( CT scan MRI ) History intracranial bleeding , confirm arteriovenous malformation , aneurysm uncontrolled coagulopathy Preexisting neurological disorder intracranial disease , e.g . multiple sclerosis Subjects leave ventricular aneurysm akinesis Subjects atrial fibrillation/atrial flutter ( chronic intermittent ) Subjects another source right leave shunt identify baseline , include atrial septal defect and/or fenestrated septum Subjects could undergo TEE examination Subjects contraindication aspirin Clopidogrel therapy Pregnant desire become pregnant within next year Subjects underlying malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>PFO</keyword>
	<keyword>Stroke</keyword>
</DOC>